{"entity":{"id":"resolution-ctdx-first","kind":"drug","name":"Resolution ctDx FIRST","aka":[],"tldr":"A blood test approved with adagrasib to find the KRAS G12C mutation in lung cancer when a tissue biopsy is not possible.","summary":"Agilent's Resolution ctDx FIRST was approved by the FDA in December 2022 alongside adagrasib as a liquid biopsy companion diagnostic for KRAS G12C-mutant non-small-cell lung cancer, with tumour-profiling claims for other lung cancer genes. It is the second liquid comprehensive genomic profiling test with a companion claim after Guardant360 CDx and FoundationOne Liquid CDx. As with all plasma tests, a negative result should be followed by tissue testing.","status":"approved","asOf":"2026-09-10","links":[{"label":"Agilent: Resolution ctDx FIRST","url":"https://www.agilent.com/en/product/liquid-biopsy/resolution-ctdx-first"}],"tags":["test"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["liquid-biopsy","companion-diagnostic"],"targets":["kras"],"drugs":["adagrasib"],"companies":["agilent"],"institutions":[],"pathways":[],"terms":["ctdna"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["What a result means: KRAS G12C detected in blood makes adagrasib or sotorasib an option after first-line treatment."],"brand":"Resolution ctDx FIRST","modality":"Liquid biopsy companion diagnostic test (NGS, cfDNA)","mechanism":"Targeted NGS of plasma cell-free DNA covering lung cancer driver genes, with a companion claim for KRAS G12C.","approvals":[{"region":"US","year":2022,"indication":"Companion diagnostic for adagrasib in KRAS G12C-mutant NSCLC (plasma)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/resolution-ctdx-first/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"drug":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/"}],"company":[{"id":"agilent","kind":"company","name":"Agilent Technologies (Dako)","route":"/companies/agilent/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"}]}}